Short Interest in Immatics (NASDAQ:IMTXW) Declines By 8.5%

Immatics (NASDAQ:IMTXW) saw a significant decline in short interest in January. As of January 15th, there was short interest totalling 15,100 shares, a decline of 8.5% from the December 31st total of 16,500 shares. Based on an average daily trading volume, of 34,400 shares, the short-interest ratio is presently 0.4 days.

Immatics Price Performance

NASDAQ IMTXW traded down $0.01 during trading on Monday, hitting $0.04. The company’s stock had a trading volume of 400 shares, compared to its average volume of 63,700. The business’s 50 day simple moving average is $0.21 and its 200-day simple moving average is $1.37. Immatics has a fifty-two week low of $0.02 and a fifty-two week high of $4.14.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.